首页> 外文期刊>Modern Pathology >Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis
【24h】

Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis

机译:通过主观子宫内膜上皮内瘤变诊断来预测子宫内膜癌

获取原文
       

摘要

Endometrial intraepithelial neoplasia (also known as 'EIN') is a precursor to endometrioid endometrial adenocarcinoma characterized by monoclonal growth of mutated cells, a distinctive histopathologic appearance, and 45-fold elevated cancer risk. We have applied diagnostic criteria for EIN to 97 successive endometrial biopsies classified as hyperplastic according to World Health Organization criteria and correlated results with computer-assisted morphometry (D-score) and clinical cancer outcomes. Three pathologists separately reviewed all cases for presence or absence of EIN using published criteria (gland area>stromal area, cytologic change in focus of altered architecture, lesion size >1mm, and exclusion of cancer and mimics). Discordant cases were resolved by a consensus review at a multiheaded scope. Clinical outcomes were obtained in 84 patients from patient visit and pathology records. Diagnoses of presence or absence of EIN were unanimous among all three pathologists in 75% of cases, and intraobserver-reproducibility was very good (kappa 0.73–0.90). Cases rediagnosed as EIN encompassed hyperplasias previously diagnosed as atypical (n=18) or nonatypical (eight complex, two simple). Eight follow-up cancers were scattered between hyperplasia types (5/21 atypical, 3/63 nonatypical), but all classified as EIN (8/25) and D-score 1 (8/38). Subjective application of criteria for diagnosis of EIN correlates well with objective morphometry and successfully segregates patients into high and low cancer risk subgroups with better reproducibility than atypical hyperplasia diagnosis.
机译:子宫内膜上皮内瘤变(也称为“ EIN”)是子宫内膜样子宫内膜腺癌的前体,其特征在于突变细胞的单克隆生长,独特的组织病理学外观和高45倍的癌症风险。根据世界卫生组织的标准,我们已将EIN的诊断标准应用于97例连续增生的子宫内膜活检,并将结果与​​计算机辅助形态学(D-评分)和临床癌症结局相关联。三名病理学家使用已公布的标准(腺体面积>基质面积,结构改变重点的细胞学变化,病变大小> 1mm以及排除癌症和模拟物)分别审查了所有病例是否存在EIN。不协调的案件通过多头共识协商解决。从患者就诊和病理记录中获得了84例患者的临床结果。在三分之七的病例中,三位病理学家对EIN的存在与否均没有一致的诊断,并且观察者的可重复性非常好(kappa为0.73-0.90)。重新诊断为EIN的病例包括先前被诊断为非典型(n = 18)或非典型(八个复杂,两个简单)的增生。八个随访癌散布在增生类型之间(非典型性为5/21,非典型性为3/63),但均分为EIN(8/25)和D评分1(8/38)。 EIN诊断标准的主观应用与客观形态学密切相关,并成功地将患者分为高危和低癌风险亚组,其重现性高于非典型增生诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号